Enrolling By Invitation PHASE2 INTERVENTIONAL 1-arm
NCT07359404
Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC
A Phase II Clinical Study of Sacituzumab Govitecan Combined With Bevacizumab for the Treatment of Patients With Metastatic Triple-Negative Breast Cancer
Sponsor: YING FAN
Conditions
Advanced Breast Cancer
Interventions
Bevacizumab Sacituzumab Govitecan (SG)
Updated 1 time since 2026 Last updated: Jan 13, 2026 Started: Apr 1, 2024 Primary completion: Dec 31, 2026 Completion: Dec 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT07359404, this PHASE2 trial focuses on Advanced Breast Cancer and remains ongoing. Sponsored by YING FAN, it has been updated 1 time since 2024, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
1 version recorded Enrolling By Invitation — PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- YING FAN
Data source: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
For direct contact, visit the study record on ClinicalTrials.gov .